Looking for an innovative approach to treating newly diagnosed glioblastoma (ndGBM) [WHO grade 4 glioma*]?
Watch our on-demand webinar series that discusses the latest clinical data and real-world evidence for the use of Optune Gio in patients with newly diagnosed GBM, and hear expert opinion on how to integrate Optune Gio into patients’ daily lives.
Optune Gio in the Real World: Improving Survival in Patients With ndGBM [WHO Grade 4 Glioma*]
Dr Matthew Ballo, Medical Director of Radiation Oncology, West Cancer Center & Research Institute, Memphis, Tennessee, USA (Chair)
Professor Josef Vymazal, Head of Radiology, Na Homolce Hospital, Prague, Czech Republic
Watch Dr Ballo and Professor Vymazal, discuss the landmark EF-14 trial and real-world evidence of Optune Gio in patients with ndGBM, before sharing their clinical experiences of delivering and managing Optune Gio.†
Integrating Optune Gio into Everyday Life in Patients With ndGBM [WHO Grade 4 Glioma*]
Dr Martin Misch, Department of Neurosurgery, Charité Universitätsmedizin Berlin, Germany
Watch this focussed expert experience lecture by Dr Misch on the practical management of Optune Gio use, including discussion on patient quality of life and the management of common adverse events.†
ndGBM, newly diagnosed glioblastoma
*Reclassification of ndGBM according to the 2021 WHO classification of tumours of the central nervous system, now refers to WHO grade 4 glioma.1
†Novocure cannot provide medical advice.
Reference:
1. Optune User Manual. https://manuals.novocure.eu/. Accessed 02 January 2024.